Recombinant CDKN2A Antibody / p16INK4a

Western blot: 1-2ug/ml,Immunohistochemistry (FFPE): 1-2ug/ml

p16INK4a is a tumor suppressor protein. It is a specific inhibitor of cdk4/cdk6, and a tumor suppressor involved in the pathogenesis of a variety of malignancies. Recent analyses of the p16INK4a gene revealed homozygous deletions, nonsense, missense, or frameshift mutations in several human cancers. Although the frequency of p16INK4a abnormalities is higher in tumor derived cell lines than in unselected primary tumors, significant subsets of clinical cases with aberrant p16INK4a gene have been reported among melanomas, gliomas, esophageal, pancreatic, lung, and urinary bladder carcinomas, and some types of leukemia. Expression of p16INK4a (p16 positive) is highly correlated with human papilloma virus (HPV) infection in head and neck squamous cell carcinomas (HNSCC). p16 status is an important prognostic indicator in HNSCC and the p16 positive/HPV16 negative group is likely a distinct subgroup lacking any HPV genotype.

Purified

1 mg/ml in 1X PBS; BSA free, sodium azide free

Purified recombinant prokaryotic full-length human p16INK4a protein was used as the immunogen for the recombinant CDKN2A antibody.

Nucleus, Cytoplasm

Protein A/G affinity

P42771